Skip to contentpdufa.bio

emavusertib (CA-4948)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

emavusertib (CA-4948) is a Curis Inc program in frontline chronic lymphocytic leukemia. Its next catalyst is a Readout in Dec 2026.

CRIS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Frontline chronic lymphocytic leukemia. Sponsor: Curis Inc (CRIS). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 2026CRIS

Questions

When is emavusertib (CA-4948)'s next FDA decision or readout?

The next tracked catalyst for emavusertib (CA-4948) is a Readout in Dec 2026.

What happened at emavusertib (CA-4948)'s most recent FDA decision?

No FDA decision for emavusertib (CA-4948) is in our archive yet.

What is emavusertib (CA-4948) used for?

In our records emavusertib (CA-4948) is under review or in development for Frontline chronic lymphocytic leukemia.

Who makes emavusertib (CA-4948)?

Curis Inc (CRIS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.